<DOC>
	<DOCNO>NCT02551731</DOCNO>
	<brief_summary>Infantile Spasms ( IS ) diagnosis describe fairly rare terrible form epilepsy usually strike child first year life . There great need safe effective therapy treatment IS . This need even important infant toddler still sick treated medicine already available . This multi-center study evaluate efficacy safety Cannabidiol Oral Solution ( COS ) treatment child age 6 month 36 month diagnosis infantile spasm respond first line therapy . The overall study duration expect 64 week subject respond COS treatment . The maximum possible study duration patient approximately 64 week , however subject deem complete study 58 week .</brief_summary>
	<brief_title>Cannabidiol Oral Solution Treatment Refractory Infantile Spasms</brief_title>
	<detailed_description>A protocol amendment May 2016 create two part trial : Part A ( extended treatment period ) Part B ( safety treatment period ) , whose objective follow : Primary Part A : To evaluate efficacy Cannabidiol Oral Solution treat refractory infantile spasm ( IS ) . Secondary : Part A : - To evaluate safety Cannabidiol Oral Solution treat refractory infantile spasm . Part B : - To assess long-term safety Cannabidiol Oral Solution adjunctive treatment subject Infantile Spasms ( IS ) - To establish continued efficacy Cannabidiol Oral Solution maintain seizure control subject IS - To assess global status subject take Cannabidiol Oral Solution extend period time determine various qualitative assessment - To monitor change plasma level Cannabidiol Oral Solution long-term treatment subject IS</detailed_description>
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Spasms , Infantile</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Meets protocolspecified criterion qualification , include infantile spasms Parent ( ) /caregiver ( ) fully comprehend sign inform consent form , understand study procedure , communicate satisfactorily Investigator study coordinator . History current use overthecounter medication , dietary supplement , drug outside protocolspecified parameter Signs , symptoms history condition , per protocol opinion investigator , might compromise : 1. safety wellbeing participant study staff 2. analysis result During Safety Treatment Followup Periods , subject receive following : 1. cannabinoids ( CBD , Î”9tetrahydrocannabinol ( THC ) , hemp oil , Realm Oil marijuana ) 2. investigational drug investigational device</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>